{"preliminary_commentary":{"by_channel":{"youtube":7,"podcast":6,"x_thread":3},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT05386108\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"name":"ELECTRA","nct_id":"NCT05386108","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=electra-nct05386108. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1250,"size":"standard","size_rule":"Standard: 151–300 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"ELECTRA","arms":[{"description":"Elacestrant 300 milligrams (mg) once daily (QD) + abemaciclib 100 mg twice daily (BID)","label":"Phase 1b Cohort 1","type":"EXPERIMENTAL"},{"description":"Elacestrant 400 mg QD + abemaciclib 100 mg BID","label":"Phase 1b Cohort 2","type":"EXPERIMENTAL"},{"description":"Elacestrant 400 mg QD + abemaciclib 150 mg BID","label":"Phase 1b Cohort 3","type":"EXPERIMENTAL"},{"description":"Elacestrant in combination with abemaciclib at the RP2D determined in Phase 1b","label":"Phase 2","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2026-12","type":"ESTIMATED"},"conditions":["Breast Neoplasms","Brain Neoplasms","Neoplasms by Site","Neoplasms","Breast Diseases","Central Nervous System Neoplasms","Brain Diseases","Central Nervous System Diseases"],"enrollment":{"count":73,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"Elacestrant","otherNames":["Elacestrant dihydrochloride","RAD-1901","ER-306323","Orserdu"],"type":"DRUG"},{"name":"Abemaciclib","otherNames":["Verzenio"],"type":"DRUG"}],"last_update":"2026-10-09","lead_sponsor":"Stemline Therapeutics, Inc.","official_title":"An Open-label Multicenter Phase 1b-2 Study of Elacestrant in Combination With Abemaciclib in Women and Men With Brain Metastasis From Estrogen Receptor Positive, HER-2 Negative Breast Cancer","overall_status":"RECRUITING","phases":["PHASE1","PHASE2"],"primary_completion_date":{"date":"2026-12","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Phase 1b: RP2D","timeFrame":"Cycle 1 (28 days)"},{"measure":"Phase 2: Objective Response Rate (ORR) Per Overall Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST V1.1)","timeFrame":"3 years"}],"references":[],"start_date":{"date":"2022-08-31","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Study of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due to ER+/HER-2- Breast Cancer","url":"https://clinicaltrials.gov/study/NCT05386108"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/electra-nct05386108"}